Thirty‐one percent of patients within a male medium secure unit (MMSU) were identified with treatment resistant schizophrenia. Almost half of these patients had not received clozapine treatment at least once during the course of their treatment history. The authors recommend that early identification of these patients and the appropriate use of therapeutic treatments, including clozapine, could lead to better outcomes for patients and significant cost savings for the NHS.

The antidepressant agomelatine combines a novel mechanism of action with certain advantages over currently available antidepressants, in terms of restoration of sleep, absence of treatment-emergent sexual dysfunction, and fewer discontinuation symptoms. What is its potential role in clinical practice?

No abstract